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Abstract
Summary The aim of this study was to evaluate fracture risk
after onset of myasthenia gravis using the UK General
Practice Research Database. Overall fracture risk is not statis-
tically increased compared with age- and gender-matched
controls irrespective of glucocorticoid use, but was increased
in those using antidepressants, anxiolytics or anticonvulsants.
Introduction Myasthenia gravis (MG) is a neuromuscular
disease which has been associated with an increased falls
risk and glucocorticoid-induced osteoporosis, recognized
determinants of increased fracture risk. The aim of this
study was to evaluate the risk of fracture after onset of
MG.
Methods We conducted a retrospective cohort study using
the UK General Practice Research Database (1987–2009).
Each MG patient was matched by age, sex, calendar time
and practice to up to six patients without a history of MG
and we identified all fractures and those associated with
osteoporosis.
Results Compared to the control cohort, there was no
statistically significant increased risk observed in patients
with MG for any fracture (adjusted hazard ratio [AHR]
1.11; 95 % confidence interval [CI], 0.84–1.47) or osteo-
porotic fractures (AHR 0.98 [95 % CI 0.67–1.41]).
Further, use of oral glucocorticoids up to a cumulative
dose exceeding 5 g prednisolone equivalents did not in-
crease risk of osteoporotic fracture (AHR 0.99 [95 % CI,
0.31–3.14]) compared with MG patients without gluco-
corticoid exposure. However, fracture risk was higher in
patients with MG prescribed antidepressants (AHR 3.27
[95 % CI, 1.63–6.55]), anxiolytics (AHR 2.18 [95 % CI,
1.04–4.57]) and anticonvulsants (AHR 6.88 [95 % CI,
2.91–16.27]).
Conclusion Overall risk of fracture in patients with MG
is not statistically increased compared with age- and
gender-matched controls irrespective of glucocorticoid
use but was increased in those using antidepressants,
anxiolytics or anticonvulsants. These findings have impli-
cations in strategies preserving bone health in patients
with MG.
S. Pouwels :A. de Boer :H. G. Leufkens : F. de Vries
Utrecht Institute for Pharmaceutical Sciences, Universiteit Utrecht,
Utrecht, the Netherlands
M. K. Javaid : C. Cooper
Oxford NIHR Musculoskeletal Biomedical Research Unit,
Department of Orthopaedics, Rheumatology and Musculoskeletal
Sciences, University of Oxford,
Oxford, UK
D. Hilton-Jones
Department of Clinical Neurology, University of Oxford,
Oxford, UK
J. Verschuuren
Department of Neurology, Leiden University Medical Centre,
Leiden, the Netherlands
C. Cooper : F. de Vries
MRC Lifecourse Epidemiology Unit, University of Southampton,
Southampton, UK
F. de Vries
Department of Clinical Pharmacy & Toxicology,
Maastricht University Medical Centre,
Maastricht, the Netherlands
F. de Vries (*)
Universiteitsweg 99,
3584 CG Utrecht, the Netherlands
e-mail: f.devries@uu.nl
Osteoporos Int (2013) 24:467–476
DOI 10.1007/s00198-012-1970-5
Keywords Corticosteroids . Epidemiology . Fracture .
Myasthenia gravis . Osteoporosis
Introduction
Myasthenia gravis (MG) is an automimmune disorder with
symptoms of muscle weakness and fatigability, in which
antibodies reduce the number of acetylcholine receptors at
the post-synaptic region of the neuromuscular junction [1].
MG is relatively rare with an estimated pooled incidence
rate of 5.3 per million person-years and an estimated pooled
prevalence rate of 77.7 per million persons [2]. Treatment
options for MG include use of cholinesterase inhibitors and
immunosuppressants, including oral glucocorticoids and in
selected patients plasmapheresis and thymectomy [3].
Patients with a diagnosis of MG have a normal life expec-
tancy based on the currently available therapies [4].
MG is associated with an increased falls risk [5–7] and
glucocorticoid-induced osteoporosis [8, 9]. The increased
risk of falls from MG is likely to be multifactorial including
severe muscle weakness [1], impaired vision as a result of
ocular MG and steroid-induced myopathy [10, 11]. Recent
studies in a representative sample of the total UK population
have shown that treatment with glucocorticoids is associated
with a substantial risk of fracture, in a wide range of chronic
diseases [12, 13]. Oral glucocorticoid treatment in MG
patients is regularly started with 10 mg prednisolone per
day and is quickly increased towards about 60 mg per day
[14, 15]. Once an effective clinical response is obtained
(within about 10–12 weeks), this dose is slowly tapered
down, towards 2.5–10 mg prednisolone equivalents each
day or an equivalent dose on alternate days for mainte-
nance [15]. Hence these patients are routinely exposed
to significant cumulative doses of prednisolone far ex-
ceeding 1 g.
In addition to falls risk and glucocorticoid therapy, the
increased risk of fracture in patients with MG may also
relate to psychiatric comorbidity and its treatment. As com-
pared with healthy patients, MG patients are more likely to
have a history of central nervous system (CNS) disorders
[16]. This could be the result of a central cholinergic trans-
mission deficit, caused by blocking of acetylcholine recep-
tors within the central nervous system [17]. Both CNS drugs
such as antidepressants and antipsychotics, and the CNS
diseases like epilepsy and depression have been associated
with an increased risk of fracture [18–21], or osteoporosis
[22, 23].
Objectives of this study are to determine the risk of
fracture in patients with MG, as compared with population-
based controls, and to evaluate the effects of oral glucocorti-




Information for this study was obtained from the General
Practice Research Database (GPRD), which comprises the
computerized medical records of all patients under the care
of general practitioners in the UK. Medical information on
patients who are registered for medical care with a practice
is supplied to the GPRD [24]. The data in GPRD have been
linked to the national Hospital Episode Statistics (HES) in
England, for approximately 45 % of all practices. HES
includes information on the date, main discharge diagnosis
and duration of hospitalisation, as provided by the NHS
hospitals. Data were linked from April 2001 up to
March 2007. Previous studies of GPRD data have
shown a high level of data validity with respect to the
reporting of fractures (>90 % of fractures were con-
firmed) [25, 26].
Study population
A proxy for identifying MG patients was agreed upon by
two neurologists, an expert in bone diseases and a pharma-
coepidemiologist (JV, DHJ, KJ and FV). The study popula-
tion consisted of all patients aged 18 years or older with at
least one recorded diagnosis of MG during the period of
HES or GPRD data collection (for this study, GPRD data
collection started in January 1987 and ended in July 2009).
Incident cases of MG were defined as individuals whose
first recorded GP or hospital visit for MG was at least 1 year
after their inclusion into the database. Each MG patient was
matched by year of birth, sex and practice to up to six
patients without a history of MG to generate a matched
cohort. The index date of MG diagnosis was the date of
the first record of MG after GPRD data collection had
started. Each control patient was assigned the same index
date as his matched MG patient. The study patients were
followed up from this index date to either the end of GPRD
data collection, the date of transfer of the patient out of the
practice area, the patient’s death or the occurrence of frac-
ture, whichever came first. All types of fracture were in-
cluded in the analyses and classified according to the
International Classification of Diseases, Tenth Revision
(ICD-10) categories (HES) and corresponding read codes
(GPRD). A typical osteoporotic fracture was defined as a
fracture of the radius/ulna, humerus, rib, femur/hip, pelvis or
vertebrae (clinically symptomatic).
Subsequently, this population was then divided into a
group of probable MG cases (n0834) with their matched
controls and a group of possible MG cases (n0232) with
their matches controls. The following criteria were used to
determine a probable MG case: a recording of MG in two
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different registries (GPRD and HES) (n0205), or it has a
recording of MG in at least one registry with either a letter
from a neurologist confirming the patient has seen a neurol-
ogist ever before or 1 year after the diagnostic code (n0
291), or a record of thymectomy (n048) any time during
follow-up (recorded either in GPRD or HES) or at least two
prescriptions on different days of pyridostigmine, oral glu-
cocorticoids, azathioprine, methotrexate, ciclosporin or
mycophenolate mofetil any time during enrolment (n0
754). Possible cases were identified if they had a recording
of MG in either GPRD or HES without the abovementioned
prescription data, recording of thymectomy or a letter from a
neurologist. Patients were excluded if they had a record of
Lambert–Eaton type myasthenic syndrome, which mimics
MG.
Exposure
The indicators of MG severity selected for the study were
selected from the myasthenia gravis Foundation of America
postintervention status that were also recorded in the GPRD
[27]. Grade 1 included patients who did not use cholines-
terase inhibitors or immunosuppressants during the past
6 months. Grade 2 included patients who used immunosup-
pressants, but not cholinesterase inhibitors during the past
6 months. Grade 3 included patients who used pyridostig-
mine only during the past 6 months (and no immunosupres-
sants), and grade 4 included patients who had been on both
immunosuppressants and cholinesterase inhibitors. MG se-
verity grade may fluctuate over time.
Potential confounders that were determined at baseline
included body mass index (BMI), smoking status, alcohol
status and occurrence of prior fractures. Missing data for
BMI, smoking or alcohol status was treated as a separate
group in the statistical models. Potential confounders that
were determined for a time-dependent analysis during
follow-up included age, a history of chronic diseases (in-
cluding asthma/chronic obstructive pulmonary disease
(COPD), rheumatoid arthritis, thyroid disorders, renal fail-
ure, cancer, congestive heart failure, cerebrovascular dis-
ease, diabetes mellitus, inflammatory bowel disease and
secondary osteoporosis (based on the definition of FRAX
[28]), a prescription in the 6 months before an interval for
CNS medication, anti-parkinson medication, non-steroidal
antiinflammatory drugs (NSAIDs), oral glucocorticoids and
other immunosuppressants (azathioprine, ciclosporin, tacro-
limus, mycophenolate mofetil and methotrexate). In this
approach it was assumed that no residual effect was left
for medication used more than 6 months before an interval.
The use of oral glucocorticoids and CNS medication were
stratified to average daily dose in 6 months before an inter-
val, and use of oral glucorticoids was also stratified to
cumulative dose in the year before an interval. WHO
defined daily dosages were used to add up dose equivalen-
ces of various CNS medication and oral glucocorticoid
substances. Within the 6 months before each interval, the
average daily dose was calculated by dividing the cumula-
tive dose by the time between the oldest prescription and the
start date of the period. In addition, MG disease duration
was noted, as measured from the start of follow-up.
Statistical analysis
Time-dependent Cox proportional hazards regression was
used in order to estimate hazard ratios (HRs) of fracture risk.
The first analysis compared the fracture rate in MG patients
with that in control patients, to yield an estimate of the HRs
of fracture in MG. The second analysis examined the effect
of disease severity and use of oral glucocorticoids, antide-
pressants, anxiolytics or anticonvulsants on fracture risk in
the MG cohort.
For each analysis, the regression model was fitted with the
indicators for MG severity and general risk factors. These
characteristics were treated as time-dependent variables in the
analysis, in which the total period of follow-up was divided
into periods of 30 days, starting at the index date. At the start
of each period, the presence of risk factors and indicators of
MG severity were assessed by reviewing the computerized
prescription and diagnosis records prior to the right censoring
date. BMI, alcohol status, smoking status and occurrence of
prior fracture were determined at baseline. During follow-up,
the presence of a previous record for a chronic disease ever
before each period of 30 days was assessed, while the pres-
ence of a medical prescription was assessed in the 6 months
before each period. All characteristics, except age, were in-
cluded as categorical variables in the regression models. A
priori we tested for interactions between age and gender with
fracture risk. Adjustments were made if any potential con-
founder showed a change in HR exceeding 1 %.
Sensitivity analyses
A separate analysis was performed for probable and for
possible MG patients. In a second sensitivity analysis, we
excluded all patients and their matched subjects who had
ever been prescribed a bisphosphonate, selective oestrogen
receptor modulator, strontium ranelate or parathyroid hor-
mone during follow-up. This in order to evaluate whether
the use of bone protecting treatment had masked a true
association between MG or glucocorticoid use and fracture.
Results
Table 1 shows that there were 1,066 incident patients with
probable or possible MG matched to 6,392 controls identified
Osteoporos Int (2013) 24:467–476 469
between 1987 and 2009. The mean age of patients with MG
was 62 years and 50 % were female. Most patients with
incident MG (78 %) were able to be classified with probable
MG. Patients were followed for a median of 4 years.
Table 1 Baseline characteristics
of patients with incident myas-
thenia gravis and control patients
aCiclosporin, azathioprine,
tacrolimus, mycophenolate
mofetil and methotrexate are
included




Characteristics (n01,066) (n06,392) (n0834) (n0232)
Female 49.7 49.8 45.6 64.7
Mean age (years) 61.6 61.4 62.4 58.4
BMI (%)
<20 5.2 5.5 4.3 8.2
>30 21.5 16.6 22.9 16.4
Unknown 13.0 15.5 12.6 14.7
Smoking status (%)
Never 47.7 43.2 46.6 51.7
Current 13.8 17.6 13.5 14.7
Ex 23.2 22.0 25.5 14.7
Unknown 15.3 17.1 14.3 19.0
Alcohol status (%)
Never 14.7 10.4 15.2 12.9
Current 57.5 59.6 57.6 57.3
Ex 5.5 3.9 6.0 3.9
Unknown 22.2 26.1 21.2 25.9
Fracture history (%)
Any fracture 15.1 15.7 15.0 15.5
Fracture at osteoporotic sites 6.8 7.5 6.7 6.9
Hip fracture 0.8 0.6 0.8 0.4
Vertebral fracture 0.8 0.6 0.5 0.9
Radius/ulna fracture 2.8 3.9 2.6 3.4
Comorbidity ever before index date (%)
Asthma 13.1 10.5 12.8 14.2
COPD 3.0 4.2 3.1 2.6
Congestive heart failure 2.3 2.9 2.0 3.4
Diabetes mellitus 7.9 6.9 8.8 4.7
Rheumatoid arthritis 2.6 1.3 2.8 2.2
Renal failure 1.1 0.9 1.2 0.9
Cerebrovascular disease 8.0 6.1 8.8 5.2
Inflammatory bowel disease 0.8 0.8 0.7 1.3
Cancer 18.3 18.1 18.6 17.2
Thyroid disorders 18.7 11.0 18.0 21.1
Secondary osteoporosis 6.6 4.5 6.5 6.9
Drug use in 6 months before index date (%)
Pyridostigmine 13.0 0.0 16.5 0.4
Oral glucocorticoids 8.7 2.8 9.2 6.9
Immunosuppressantsa 2.2 0.4 2.8 0.0
Antidepressants 10.4 8.4 10.9 8.6
Antipsychotics 1.2 1.3 1.2 1.3
Anxiolytics 8.4 5.9 7.4 12.1
Anticonvulsants 3.3 1.8 3.2 3.4
Bisphosphonates 4.1 1.8 4.2 3.9
Hormone replacement therapy 1.9 1.7 1.6 3.0
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When compared with their matched controls, patients
with a diagnosis of MG had no increased risk of either all
fractures in both unadjusted and adjusted models (adjusted
hazard ratio (AHR) for any fracture 1.11 (95 % confidence
interval [CI] 0.84–1.47) or typical osteoporotic fractures
AHR 0.98 (95 % CI 0.67–1.41); Table 2. The fracture risk
did not differ significantly among patients with probable
MG (AHR for any fracture 0.89 [95% CI 0.67–1.25]; for
classical osteoporotic fracture AHR 0.79 [95% CI 0.50–
1.25]). In addition, no associations were observed between
incident MG patients stratified by gender and by age
categories.
We then examined the effect of exposure to medications
well known to be associated with an increased risk of
fracture (Table 3). Surprisingly, recent exposure to oral
glucocorticoids did not significantly alter fracture risk with-
in MG patients. At osteoporotic sites of incident MG
patients, fracture risk yielded an AHR of 0.81 (95 % CI
0.40–1.61) compared to MG patients who did not use oral
corticosteroids in the past 6 months. Furthermore, an aver-
age daily dose exceeding 15 mg prednisolone equivalents in
the past 6 months (AHR 1.17 [95 % CI 0.47–2.89]) or a
cumulative dose in the year prior to each interval, exceeding
5 g prednisolone equivalents (AHR 0.99 [95 % CI 0.31–
3.14]) did not significantly alter osteoporotic fracture risk.
In these analyses, osteoporotic fractures were reported in
respectively seven and four MG patients. The interaction
term between MG and oral glucocorticoids did not reach
statistical significance (p value>0.05) for any and for typi-
cal osteoporotic fractures (Table 4). Finally, a sensitivity
analysis in which 645 MG patients without exposure to
osteoporosis therapies and their 3,647 controls were left, a
diagnosis of MG did not alter risk of any (AHR 1.21 [95 %
CI 0.84–1.74]) or typical osteoporotic fracture (AHR 1.44
[95 % CI 0.89–2.34]).
Conversely, within the group of incident MG patients risk
of fracture was twofold higher in those with a recent use of
antidepressants (AHR 2.15 [95 % CI 1.22–3.79]), twofold









No MG 426 12.6 1.00 1.00
MG (any fracture) 75 14.2 1.19 (0.93–1.52) 1.11 (0.84–1.47)
Fracture at osteoporotic sites 43 8.2 1.13 (0.82–1.56) 0.98 (0.67–1.41)
Hip fracture 8 1.5 0.85 (0.41–1.77) 0.61 (0.26–1.45)b
Vertebral fracture 9 1.7 2.85 (1.31–6.18) 2.13 (0.82–5.51)c
Radius/ulna fracture 11 2.1 0.92 (0.49–1.73) 1.02 (0.51–2.04)d
Other fracture 15 2.8 1.00 (0.58–1.71) 0.86 (0.47–1.59)e
Fracture at non-osteoporotic sites 32 6.1 1.29 (0.89–1.89) 1.42 (0.93–2.17)f
By genderg
Male 27 10.5 1.11 (0.74–1.67) 0.86 (0.52–1.42)
Female 48 18.6 1.24 (0.91–1.68) 1.20 (0.86–1.69)
By age at MG diagnosish
18–39 10 12.4 1.83 (0.90–3.69) 1.76 (0.80–3.86)
40–59 10 6.5 0.68 (0.36–1.31) 0.62 (0.29–1.29)
60–69 18 14.5 1.36 (0.82–2.25) 1.42 (0.80–2.52)
70–79 25 19.5 1.29 (0.84–4.34) 1.18 (0.72–1.92)
>080 12 30.4 1.11 (0.60–2.05) 0.97 (0.47–2.00)
a Adjusted for age, gender, use of immunosuppressants, oral glucocorticoids and antidepressants in the previous 6 months, history of smoking and
alcohol use
b Additionally adjusted for anxiolytics and antipsychotics in the previous 6 months, history of asthma and cerebrovascular disease
c Additionally adjusted for use of anxiolytics, NSAIDs, anti-parkinson medication in the previous 6 months, history of COPD, rheumatoid arthritis,
asthma, secondary osteoporosis and BMI status but not for history of smoking
d Not adjusted for history of smoking
e Not adjusted for use of antidepressants in the previous 6 months and not for history of smoking
f Additionally adjusted for history of stroke in the previous year and history of hypothyroidism and secondary osteoporosis. Not adjusted for
antidepressant use and not for history of alcohol use
gMale MG patients are compared with male controls and female MG patients with female controls
hMG patients in each age group are only compared with control patients in the same age group
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higher for anxiolytics (AHR 1.80 [95 % CI 0.97–3.34]) and
fivefold increased with recent use of anticonvulsants (AHR
5.36 [95 % CI 2.76–10.39]). Typical osteoporotic fracture
risk was threefold higher within incident MG patients with
recent use of antidepressants (AHR 3.27 [95 % CI 1.63–
6.55]), twofold higher with recent use of anxiolytics (AHR
2.18 [95 % CI 1.04–4.57]) and sevenfold higher with recent
use of anticonvulsants (AHR 6.88 [95 % CI 2.91–16.27]).
None of the remaining risk factors for fracture, which are
described in the “Methods section”, showed a significant
increased or decreased risk for any fracture or for fractures
at osteoporotic sites. Finally, within the complete cohort
with both incident MG patients and control patients, the
interaction term between MG and anxiolytics showed sta-
tistical significance for osteoporotic fracture (p value<0.05).
The interaction term between MG and anticonvulsants
showed statistical significance for both osteoporotic and
any fracture (p value<0.05).
To further investigate whether a true association between
MG and fracture risk had been averaged out by a fluctuating
hazard function, we showed that MG duration was not
related to fracture risk: 1-year risk of any fracture yielded
an AHR of 1.15 (95 % CI 0.88–1.52) in patients with MG
versus population-based controls, while 5-year risk (AHRs
of 0.97 [95 % CI 0.74–1.28]) and 10-year risk (AHR 0.94
[95 % CI 0.71–1.23]) were not different. The Kaplan–Meier
curve as presented in Fig. 1 showed similar results with a
non-significant log-rank test (p value>0.05) when MG
patients were compared with control patients. In addition,
the severity of MG was not related to increased risk of
fracture (Table 5). Finally, using MG patients only from
the GPRD (without HES data) did not alter the findings.
Table 3 Risk of any and osteoporotic fracture among incident MG patients by drug exposure









MG by use of oral glucocorticoids by cumulative dose in grams prednisolone equivalents in the previous year
No oral glucocorticoid use 47 1.00 27 1.00
Any oral glucocorticoid use 28 0.88 (0.52–1.47) 16 0.75 (0.38–1.50)
<2.5 g prednisolone eq 13 0.80 (0.42–1.53) 7 0.63 (0.26–1.53)
2.5–5.0 g prednisolone eq 10 1.11 (0.54–2.26) 5 0.83 (0.31–2.25)
>05.0 g prednisolone eq 5 0.73 (0.27–1.94) 4 0.99 (0.31–3.14)
MG by history of drug use in previous 6 months
No oral glucocorticoid use 48 1.00 28 1.00
Oral glucocorticoid use 27 0.97 (0.58–1.63) 15 0.81 (0.40–1.61)
<7.5 mg prednisolone eq/day 10 0.99 (0.49–2.03) 5 0.70 (0.26–1.92)
7.5–15 mg prednisolone eq/day 8 1.00 (0.46–2.16) 3 0.57 (0.17–1.93)
>015 mg prednisolone eq/day 9 0.93 (0.44–1.99) 7 1.17 (0.47–2.89)
No antidepressant use 59 1.00 31 1.00
Antidepressant use 16 2.15 (1.22–3.79) 12 3.27 (1.63–6.55)
<20 mg fluoxetine eq/day 9 1.88 (0.92–3.86) 7 2.77 (1.18–6.50)
>020 mg fluoxetine eq/day 7 2.61 (1.18–5.80) 5 4.32 (1.64–11.38)
No anxiolytic use 61 1.00 32 1.00
Anxiolytic use 14 1.80 (0.97–3.34) 11 2.18 (1.04–4.57)
<10 mg diazepam eq/day 10 1.72 (0.85–3.47) 8 2.10 (0.90–4.86)
>010 mg diazepam eq/day 4 2.07 (0.73–5.82) 3 2.41 (0.71–8.12)
No anticonvulsant use 64 1.00 36 1.00
Anticonvulsant use 11 5.36 (2.76–10.39) 7 6.88 (2.91–16.27)
<1.0 g carbamazepine eq/day 8 4.88 (2.27–10.50) 5 5.45 (2.03–14.62)
>01.0 g carbamazepine eq/day 3 7.10 (2.13–23.62) 2 18.18 (3.88–85.15)
No antipsychotic use 74 1.00 42 1.00
Antipsychotic use 1 1.30 (0.17–9.76) 1 1.41 (0.17–11.65)
eq equivalents
a Adjusted for the same confounders as described below Table 2 for any and osteoporotic fracture, but the confounder is not added to the model if it
is similar to the drug being investigated
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Discussion
Our results show that an incident diagnosis of MG was not
associated with a statistically increased risk of fracture or
fracture at osteoporotic sites. Further the use of oral gluco-
corticoids did not alter overall fracture risk, not even when
cumulative exposure had exceed >5 g prednisolone equiv-
alents. No association was present between fracture risk and
duration or severity of MG. However, MG patients who
used CNS medication are at significantly increased risk
compared to MG patients without CNS medication.
The most striking finding of this study was that in patients
with MG, the use of oral glucocortiods and in particular in
high dosages was not associated with an increased risk of
fracture. Alternatively, this subgroup of MG patients may
have been underpowered, especially the stratification to cu-
mulative high-dose glucocorticoids, with only four reported
osteoporotic fractures in the MG population. A different
explanation for the lower HRs in MG patients on glucocorti-
coids, is that pyridostigmine may have anabolic effects, and
therefore level out any detrimental effects of glucocorticoids
[12, 13]. Cholinesterase inhibitors elevate acetylcholine levels
in MG patients [3]. In vitro studies have shown that osteo-
blasts express acetylcholine receptors, while elevated acetyl-
choline levels induced osteoblast proliferation [29, 30], which
may ultimately result in anabolic effects of bone. In theory,
the positive effects of acetylcholine on bone turnover could
level out the negative effects of oral glucocorticosteroids on
bone, which would explain our findings. Moreover, a recent
study performed by Wakata et al. [31] showed that Japanese
MG patients who received long-term (8.2 years) high-dose
prednisolone therapy (maximum 80–100 mg for 4–6 weeks)
had a 50 % reduced osteoporosis rate as compared to the
general population. A second explanation for lower HRs in
MG patients on glucocorticoids is that generally, patients
treated with glucocorticoids are exposed to an inflammatory
disease. Subsequently, the disease may increase the risk for
fracture itself, like rheumatoid arthritis [32]. This inflamma-
tory compound is generally not present in MG patients,
except for some inflammatory cells that may be present in
muscle [33]. An alternative explanation is that glucocorticoids
may decrease fracture risk associated with the disease, thus
cancelling out its adverse effects. A last explanation is that
MG patients are often treated on alternate days with gluco-
corticoids [15]. In theory, this might reduce side effects.
Despite associations of MG with falling [5–7] and with
glucocorticoid-induced osteoporosis [8, 9], our findings
Table 4 Risk of any and osteoporotic fracture among incident MG patients and controls by drug exposure






Risk of fracture at
osteoporotic site fully




MG patients Controls MG patients Controls
Drug use in previous 6 months
No oral glucocorticoid use 1.00 1.00 1.00 1.00
Oral glucocorticoid use 0.88 (0.52–1.47) 1.50 (1.02–2.20) 0.217 0.75 (0.38–1.50) 1.86 (1.23–2.83) 0.065
No antidepressant use 1.00 1.00 1.00 1.00
Antidepressant use 2.15 (1.22–3.79) 1.50 (1.15–1.96) 0.608 3.27 (1.63–6.55) 1.63 (1.18–2.27) 0.260
No anxiolytic use 1.00 1.00 1.00 1.00
Anxiolytic use 1.80 (0.97–3.34) 1.14 (0.82–1.59) 0.101 2.18 (1.04–4.57) 1.17 (0.79–1.73) 0.044
No anticonvulsant use 1.00 1.00 1.00 1.00
Anticonvulsant use 5.36 (2.76–10.39) 0.96 (0.53–1.76) 0.000 6.88 (2.91–16.27) 1.19 (0.61–2.33) 0.002
a Adjusted for the same confounders as described below Table 2 for any and osteoporotic fracture, but the confounder is not added to the model if it
is similar to the drug being investigated







Time since onset of MG (years)
Survival
Probability
Fig. 1 Kaplan–Meier survival curve for any fracture among MG
patients versus patients without MG
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showed no significantly increased risk of fracture. In con-
trast, our finding of an increased risk of fracture in users of
various classes of CNS drugs is in keeping with previous
findings [18–21, 34]. The increased fracture risk may be
caused by side effects of CNS medication, such as sedation
and dizziness, through an increased risk of falling.[35–37].
Use of antidepressants has been associated with orthostatic
hypotension [35] and the use of anticonvulsants can be
considered a marker for seizures [38]. Both orthostatic hy-
potension and seizures are risk factors for falling and sub-
sequently for fracture. In addition, the use of SSRIs has been
shown to reduce bone mineral density in humans and neg-
atively affected bone strength in rodents [39, 40] probably
due to serotonin tranporter inhibition in osteoblasts. This
can ultimately lead to an increased risk of fracture. Finally,
reduced bone mineral density has also been observed among
users of anticonvulsants through an increase of vitamin D
catabolism, resulting in an increased bone resorption [41].
MG patients using anticonvulsants had a significantly
higher fracture risk as compared with control patients using
anticonvulsants, for which the cause is unknown. MG
patients and controls using anticonvulsants were equally
distributed when stratified to a confirmed diagnosis of epi-
lepsy in the GPRD database. The same applies for a diag-
nosis of neurological pain, which makes effect modification
unlikely. This finding warrants further research.
Our study has several strengths. It is the first study that
investigated the risk of fracture in a substantial number of
MG patients, and for whom longitudinal drug exposure data
were available. It had a reasonable sample size, comprising
1,066 incident MG patients who met the inclusion criteria.
The study was population-based and compared MG patients
directly with age–gender-matched control patients from the
same general practice in a sample that is represenative for
the total UK population. This makes selection bias unlikely.
We had the ability to statistically adjust our analyses for
well-known risk factors of fracture such as gender, age,
BMI, smoking status and occurrence of prior fractures.
Our study had various limitations. We did not have
access to neurology records, including lab test results for
presence of acetylcholine receptor antibodies, which are a
diagnostic tool for MG [1]. Information on the diagnosis of
MG patients was therefore limited. For this reason, we
determined fracture risk not only among all patients with a
MG recording in either GPRD or HES, but also among more
probable MG patients with more than one recording of MG
only. We could only use variables recorded in the GPRD to
assign disease severity and classification of severity of dis-
ease could have been improved, if we would have had
access to tertiary care data such as plasmapheresis. We did
not have data on femoral bone mineral density and no data
on history of hip fracture among the parents of patients.
Only small numbers of incident MG patients were present in
the subgroup analyses. For this reason, these data should be
interpreted with care. Moreover, no data were present about
vitamin D plasma levels, degree of exercise or longitudinal
data on body weight. This could have confounded the ob-
served increased fracture risks in patients using CNS
medication.
We showed an absence of fracture risk among MG
patients using oral glucocorticoids compared to unexposed
MG patients and a lower risk compared to control patients
using oral glucocorticosteroids, but we were unable to de-
termine any significant difference. This issue warrants fur-
ther research. In theory, high-dose prednisolone might
exacerbate MG, which could have interfered with the anal-
yses. However, glucocorticoid treatment is regularly started
with a low dose, which is gradually increased [14, 15]. This
minimizes the risk of an exacerbation.
In conclusion, this study showed that MG was not asso-
ciated with a statistically significant increased fracture risk,
not even among MG patients who received high-dose oral
Table 5 Risk of any fracture and fracture at osteoporotic sites in incident MG patients, by severity compared to patients without MG









MG by severity steps based on pyridostigmine and immunosuppressants use in the 6 months priorb
Grade 1: no use 28 1.00 15 1.00
Grade 2: immunosuppressants only 13 0.67 (0.16–2.80) 6 0.81 (0.13–5.04)
Grade 3: pyridostigmine only 17 0.99 (0.54–1.83) 11 1.14 (0.51–2.54)
Grade 4: both immunosuppressant
and pyridostigmine use
17 0.34 (0.07–1.60) 11 0.48 (0.07–3.42)
a Adjusted for the same confounders as described below Table 2 for any and osteoporotic fracture, but the confounder is not added to the model if it
is similar to the drug being investigated
b Immunosuppressants involved are oral glucocorticoids, azathioprine, tacrolimus, cyclosporine, mycophenolate mofetil and methotrexate
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glucocorticoids. This suggests that there is no need to alter
current management of MG. In contrast, fracture risk was
increased among patients using CNS medication. Therefore,
fracture risk assessment may be indicated among patients
with MG who have recently used CNS medication. Further
investigation should be performed to address the underlying
mechanism for the observed absence of an increased frac-
ture risk among MG patients exposed to high-dose oral
glucocorticoids.
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